Zohreh Borzooy1, Seyed Mohammad Jazayeri2, Abbass Mirshafiey3, Azam Khamseh4, Masoud Karkhaneh Mahmoudie4, Pedram Azimzadeh5, Babak Geravand6, Mohammad Ali Boroumand7, Mina Afshar8, Vahdat Poortahmasebi9, Mostafa Hosseini10, Adrian Streinu-Cercel11. 1. PhD student, Ms, Department of Infectious Diseases, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Immunology and Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 2. MD, PhD, Clinical virologist, Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 3. Ms, PhD, Head of the Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 4. Bs, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 5. Ms, Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 6. Ms, Ministry of Health and Medical Education, Tehran, Iran. 7. MD, Pathologist, Department of Pathology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. 8. Bs, Tehran University of Medical Sciences, Mirza Kouchak Khan Hospital, Tehran, Iran. 9. Ms, PhD student, Virologist, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 10. Ms, PhD, Department of Epidemiology and Biostatistics School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 11. MD, PhD, Professor, Department of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; National Institute of Infectious Diseases, "Prof. Dr. Matei Balş", Bucharest, Romania.
Abstract
BACKGROUND: Worldwide, healthcare workers (HCWs) show different levels of response to hepatitis B virus (HBV) vaccine. One of the factors associated with vaccine unresponsiveness may be the existence of current or past HBV infection. Regardless of the presence of HBsAg (overt infection), occult HBV infection (OBI, defined as presence of HBV DNA in the absence of HBsAg) might also account for some non- or hypo-response cases. METHODS: Sera from 120 HBsAg-negative HCWs with low and moderate levels of anti-HBs, <10 IU/mL (group I) and <100 IU/mL (group II) respectively, were selected and were examined for OBI by sensitive real-time PCR regardless of HBV serological profiles. Direct sequencing on surface genes was carried out in OBI-positive cases. RESULTS: Four (3.3%) were positive for OBI. All were negative for anti-HBc. Two of the positive cases had moderate levels of anti-HBs (>10 to <100 IU/mL). No significant differences were found between the two groups in terms of risk factors or serological data. No mutations were found in surface proteins of OBI cases. CONCLUSION: OBI in these subjects might be due to other factors rather than presence of "a" determinant mutations. Healthcare workers with inadequate to moderate levels of anti-HBs (<100 IU/mL) following vaccination, regardless of their serological profile for HBV, should be tested for the presence of HBV DNA by sensitive molecular tests. Anti-HBc is not a reliable marker for suspicion of OBI, especially in high-risk group individuals.
BACKGROUND: Worldwide, healthcare workers (HCWs) show different levels of response to hepatitis B virus (HBV) vaccine. One of the factors associated with vaccine unresponsiveness may be the existence of current or past HBV infection. Regardless of the presence of HBsAg (overt infection), occult HBV infection (OBI, defined as presence of HBV DNA in the absence of HBsAg) might also account for some non- or hypo-response cases. METHODS: Sera from 120 HBsAg-negative HCWs with low and moderate levels of anti-HBs, <10 IU/mL (group I) and <100 IU/mL (group II) respectively, were selected and were examined for OBI by sensitive real-time PCR regardless of HBV serological profiles. Direct sequencing on surface genes was carried out in OBI-positive cases. RESULTS: Four (3.3%) were positive for OBI. All were negative for anti-HBc. Two of the positive cases had moderate levels of anti-HBs (>10 to <100 IU/mL). No significant differences were found between the two groups in terms of risk factors or serological data. No mutations were found in surface proteins of OBI cases. CONCLUSION: OBI in these subjects might be due to other factors rather than presence of "a" determinant mutations. Healthcare workers with inadequate to moderate levels of anti-HBs (<100 IU/mL) following vaccination, regardless of their serological profile for HBV, should be tested for the presence of HBV DNA by sensitive molecular tests. Anti-HBc is not a reliable marker for suspicion of OBI, especially in high-risk group individuals.
Entities:
Keywords:
HBV; HBV vaccine; Healthcare workers; hepatitis B virus
Authors: I Cacciola; T Pollicino; G Squadrito; G Cerenzia; D Villari; R de Franchis; T Santantonio; S Brancatelli; G Colucci; G Raimondo Journal: Hepatology Date: 2000-02 Impact factor: 17.425
Authors: M G Chedid; H Deulofeut; D E Yunis; M L Lara-Marquez; M Salazar; R Deulofeut; Z Awdeh; C A Alper; E J Yunis Journal: Hum Immunol Date: 1997-11 Impact factor: 2.850
Authors: L Jarrosson; M N Kolopp-Sarda; P Aguilar; M C Béné; M L Lepori; M C Vignaud; G C Faure; C Kohler Journal: Vaccine Date: 2004-09-09 Impact factor: 3.641
Authors: Anna Szymanek-Pasternak; Krzysztof A Simon; Sylwia Serafińska; Justyna Janocha-Litwin; Monika Pazgan-Simon; Grzegorz Madej Journal: Clin Exp Hepatol Date: 2016-11-28